Pancreatic CancerNCT07713823
Study on the Construction and Application of a Large Model Corpus for Pancreatic Cancer Based on Real Clinical Cases
An observational study of Pancreatic Cancer and Pancreatic Cancer Metastatic, run by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine.
Trial summary
Combining retrospective observational research with artificial intelligence data engineering. Collecting historical electronic medical record data, and through data governance and annotation by artificial medical experts, constructing a structured knowledge base. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Pancreatic Cancer, Pancreatic Cancer Metastatic, Pancreatic Cancer Non-resectable
- How many people
- 3,000 participants
- Where
- No sites listed yet
- Study dates
- 1 Aug 2026to 31 May 2028
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Real pancreatic cancer diagnosis and treatment cases treated in the hospital
Who may be able to join
- Real inpatient cases of pancreatic cancer diagnosis and treatment;
- Prioritize the inclusion of cases with MDT discussion records, difficult and complex cases, and fatal cases;
- Possess complete electronic medical information (including but not limited to: outpatient medical records, inpatient medical records including admission records, progress notes, surgery/procedure records, nursing records, examination and test reports, doctor's orders, discharge/death records, etc.); -
Who cannot join
- Cases that only underwent a brief transition in emergency/outpatient departments and did not form a closed loop of diagnosis and treatment;
- Cases with incomplete diagnosis and treatment information and missing key indicators.
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Combining retrospective observational research with artificial intelligence data engineering. Collecting historical electronic medical record data, and through data governance and annotation by artificial medical experts, constructing a structured knowledge base.
- Conditions
- Pancreatic Cancer, Pancreatic Cancer Metastatic, Pancreatic Cancer Non-resectable, Pancreatic Cancer Resectable
- Medical subject headings
- Pancreatic Neoplasms
What is being measured
The primary outcome is the main question the study is designed to answer.
3,000 Cases of Pancreatic Cancer Diagnosis and Treatment
Measured: May 2028
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Jul 2026
- Study start1 Aug 2026 (estimated)
- Primary completion31 Jul 2027 (estimated)
- Study completion31 May 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Pancreatic CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Retrospective
- Enrolment
- 3,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Jiang Long, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07713823
- Sponsor's protocol ID
- IIT2026-152
- Status last verified
- Jul 2026
- First submitted
- 13 Jul 2026
- Last updated
- 21 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 21 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Study on the Construction and Application of a Large Model Corpus for Pancreatic Cancer Based on Real Clinical Cases
- ClinicalTrials.gov ID
- NCT07713823
- Acronym / sponsor ID
- IIT2026-152
- Conditions
- Pancreatic Cancer, Pancreatic Cancer Metastatic, Pancreatic Cancer Non-resectable, Pancreatic Cancer Resectable
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 3,000 participants (estimated)
- Lead sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineUniversity, hospital or other
- Study start
- 1 Aug 2026 (estimated)
- Primary completion
- 31 Jul 2027 (estimated)
- Study completion
- 31 May 2028 (estimated)
- First posted
- 20 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Combining retrospective observational research with artificial intelligence data engineering. Collecting historical electronic medical record data, and through data governance and annotation by artificial medical experts, constructing a structured knowledge base.
Study design
- Observational model
- Case only
- Time perspective
- Retrospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Real pancreatic cancer diagnosis and treatment cases treated in the hospital
Key inclusion criteria (3 listed)
- Real inpatient cases of pancreatic cancer diagnosis and treatment;
- Prioritize the inclusion of cases with MDT discussion records, difficult and complex cases, and fatal cases;
- Possess complete electronic medical information (including but not limited to: outpatient medical records, inpatient medical records including admission records, progress notes, surgery/procedure records, nursing records, examination and test reports, doctor's orders, discharge/death records, etc.); -
Key exclusion criteria (2 listed)
- Cases that only underwent a brief transition in emergency/outpatient departments and did not form a closed loop of diagnosis and treatment;
- Cases with incomplete diagnosis and treatment information and missing key indicators.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
3,000 Cases of Pancreatic Cancer Diagnosis and Treatment
Time frame: May 2028
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Jul 2026.
- Individual participant dataSharing planned: No
Related trials for Pancreatic Cancer
RecruitingPhase 1/2
A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
RecruitingPhase 2
Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder
Adjustment Disorder, Adjustment Disorder With Anxious Mood
RecruitingObservational study
Cancer in Inherited Bone Marrow Failure Syndromes
Diamond Blackfan Anemia, Dyskeratosis Congenita
RecruitingEarly Phase 1
Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Pancreatic Cancer
Pancreatic Cancer
RecruitingPhase 1
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
Solid Tumor, Non-Small-Cell Lung Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
An observational study of Pancreatic Cancer and Pancreatic Cancer Metastatic, run by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 21 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Long Jiang, MD (18017317460, jiang.long@shgh.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
3,000 Cases of Pancreatic Cancer Diagnosis and Treatment (time frame: May 2028). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Jul 2026.